BeBetter Med Inc. is a clinical-stage drug discovery and development company based in Guangzhou, China. BeBetter Med Inc. was founded in 2012 by overseas returnees, aimming to create advanced novel medicines to treat cancers, autoimmune diseases, metabolic diseases and other severe diseases. Through the years, we have developed strong expertise and outstanding facilities to perform comprehensive pharmaceutical research from compound design and synthesis to clinical development. The company expects to launch several new drugs over the next few years.
BeBetter Med’s BEBT-209 Approved for Phase III Clinical Trials
On December 18, 2021, the National Center for Drug Evaluation (CDE) approved Guangzhou BeBetter Med Inc. to develop BEBT-209 combined with Fulvestrantin the treatment of HR+/HER2- advanced breast cancer III Phase III clinical trial, titled "BEBT-209
First-In-Class Drug RGRN-305 (BEBT-305) Clinical Proof-of-Concept Study Results Published in British Journal of Dermatology
The executive director of the International Psoriasis Associationand Professor Las Iversen’s team from Denmark published "HSP90 inhibitor RGRN-305 for oral treatment of plaque type psoriasis: efficacy, safety and biomarker results in an open-label
First-In-Class Drug BEBT-908 Research Results of BEBT-908 Published on CANCER RESEARCH
The research outcomes of our company’s First-In-Class drug BEBT-908 have been published as a research paper "A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy" (PI3K/HDAC dual-target inhi
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号